| Drug Name |
Carboplatin |
| Drug ID |
BADD_D00364 |
| Description |
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523]
Carboplatin was granted FDA approval on 3 March 1989.[L32248] |
| Indications and Usage |
For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01XA02 |
| DrugBank ID |
DB00958
|
| KEGG ID |
D01363
|
| MeSH ID |
D016190
|
| PubChem ID |
426756
|
| TTD Drug ID |
D0X7HM
|
| NDC Product Code |
0703-4239; 55150-335; 63592-0271; 68083-192; 49812-0010; 68554-0084; 53104-7570; 69448-005; 0703-4246; 54875-0002; 55150-386; 55150-334; 0703-4248; 55150-333; 63323-172; 72659-863; 68083-191; 71288-100; 16729-295; 0703-4244; 68083-193; 68083-190; 61703-339 |
| Synonyms |
Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb |
